July 1, 2021

On Wednesday, June 30, 2021, CureVac N.V. (Nasdaq: CVAC) announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.

The company hosted a conference call and webcast on Thursday, July 1, 2021, 2:00 p.m. CET / 8:00 a.m. EDT.

A replay of the webcast can be found under "Links".